Mental Health Prescribers’ Perceptions on the Use of Pharmacogenetic Testing in the Management of Depression in the Middle East and North Africa Region

Figures & data

Table 1 Participants’ Characteristics

Characteristics	N (%)
Gender
Male	13 (72.2)
Female	5 (27.8)
Age
30–40	6 (33.4)
41–50	2 (11)
51–60	7 (38.9)
>60	3 (16.7)
Country of practice
Qatar	4 (22)
Saudi Arabia	3 (16.7)
Bahrain	2 (11)
Jordan	1 (5.6)
Egypt	1 (5.6)
Tunisia	1 (5.6)
Oman	1 (5.6)
Palestine	1 (5.6)
Iraq	1 (5.6)
Kuwait	1 (5.6)
United Arab Emirates	1 (5.6)
Algeria	1 (5.6)
Degree
Senior consultant	12 (66.6)
Specialist	3 (16.7)
Assistant professor with board certification	1 (5.6)
Physician	1 (5.6)
Senior registrar	1 (5.6)
Years of practicing psychiatry
<5	2 (11)
6-15	4 (22)
16–25	6 (33.4)
>25	6 (33.4)
Settings
Mixed settings	15 (83.3)
Outpatient	3 (16.7)

Table 2 Major Overarching Themes

Themes	Subthemes
1. Overall perceptions and attitudes	1a. Enabling perceptions and attitudes 1b. Disabling perceptions and attitudes 1c. Indications to request PGx testing
2. Knowledge and awareness	2a. Overall good awareness 2b. Overall basic knowledge
3. Education, training, and professional experience	3a. Limited education, training, and professional experience 3b. Qualifications and training needs
4. Facilitators and barriers	4a. Facilitators for implementing PGx 4b. Barriers for the uptake of PGx strategies
5. Ethical dilemmas	5a. Informed consent and confidentiality 5b. Transparency